^ abGreenblatt EN, Osterberg AC (July 1965). "Some pharmacologic properties of thozalinone, a new excitant". Toxicology and Applied Pharmacology. 7 (4): 566–78. doi:10.1016/0041-008X(65)90042-6. PMID4378772.
^Merck index on CD-ROM: Windows. London: Chapman & Hall EPD. 1998. ISBN0-412-82910-X.
^Gallant DM, Bishop MP, Scrignar CB, Hornsby L, Moore B, Inturrisi BB (December 1966). "A double-blind study of thozalinone (C1 39,808) in depressed outpatients". Current Therapeutic Research, Clinical and Experimental. 8 (12): 621–2. PMID4962734.
^Leite AC, Liepen LL, Costa VP (September 1971). "[Clinical trial of Stimsem Thozalinone in the treatment of obese patients]". Revista Brasileira de Medicina (in Portuguese). 28 (9): 475–8. PMID5139648.
^ abYen-Koo HC, Balazs T (1980). "Detection of dopaminergic supersensitivity induced by neuroleptic drugs in mice". Drug and Chemical Toxicology. 3 (2): 237–47. doi:10.3109/01480548009108286. PMID6112126.
^Yen-Koo HC, Davis DA, Balazs T (1985). "Inhibition of dopaminergic agonist-induced gnawing behavior by neuroleptic drugs in mice". Drug and Chemical Toxicology. 8 (6): 495–502. doi:10.3109/01480548509041072. PMID2868876.